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Abstract
Objective—Recent increases in the nonmedical use of pharmaceutical opioids and the adverse 
outcomes associated with them have stimulated a large amount of research and data collection on 
this public health problem. Systematic organization of the available data sources is needed to 
facilitate ongoing research, analysis, and evaluation. This work offers a systematic categorization 
of data sources regarding the nonmedical use of pharmaceutical opioids in the United States.
Methods—A list of keywords regarding the nonmedical use of pharmaceutical opioids was used 
to conduct systematic searches in PubMed®. Filtration of search results generated 92 peer-
reviewed academic articles, published between January 1995 and April 2012, as well as a number 
of primary data sources. Lists of topics were developed independently by two researchers which 
were later compared and consolidated. All sources were then categorized according to their 
relevance to each of these topics and according to their capacity for geographical and longitudinal 
trend analysis.
Results—Tables cataloging data sources can be used to identify data relevant to specific topics 
in diversion, nonmedical use, and adverse outcomes associated with pharmaceutical opioids, and 
they illustrate global trends in data coverage, identifying several topics that have minimal data. A 
network diagram illustrates global trends in data coverage, showing variation among sources in 
the number of topics they cover, as well as variation among topics in the number of sources that 
cover them.
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Directions for Further Research Researchers, policymakers, and other professionals in the health care field are encouraged to refer 
to the tables in this article when identifying data sources for ongoing research, analysis, and evaluation of this public health problem. 
In addition, data collection efforts are needed to address several topics that appear to have few data sources covering them, including 
nonmedical use frequency, addiction relapse, polydrug use, availability of pharmaceutical opioids for nonmedical use, domestic 
impact, and transaction tracking. With relatively few data sources identified, measurement of these topics would likely be beneficial 
for understanding and ameliorating the diversion, nonmedical use, and adverse outcomes associated with pharmaceutical opioids in 
the United States.
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Conclusions—The categorization of data sources is hoped to facilitate ongoing research, 
analysis, and evaluation of this public health problem by serving as a guide for researchers, policy 
makers, and others who seek data regarding the nonmedical use of pharmaceutical opioids in the 
United States.
Keywords
nonmedical use; diversion; adverse outcomes; pharmaceutical opioids; data sources
A dramatic rise in the nonmedical use of pharmaceutical opioids presents the United States 
with a substantial public health problem [1]. The 2011 National Survey of Drug Use and 
Health (NSDUH) estimates that 2.3 percent of the US population used pain relievers 
nonmedically during the past month, and that at least 1.9 million individuals have initiated 
nonmedical use each year since 2002 [2]. Such medications are now among the most 
popular drugs for nonmedical use, second only to marijuana [3], and are associated with a 
variety of adverse outcomes. The number of overdose deaths involving opioids increased 
threefold between 1999 and 2006, and fivefold among youth aged 15 to 24 [4]. Use 
disorders involving pain reliever abuse or dependence were estimated to afflict 1.4 million 
individuals in 2011, one third of whom were young adults between the ages of 18 and 25 
[2]. Many of the pharmaceutical opioids that are used nonmedically are diverted in some 
way from their legally intended purpose: Over half of nonmedical users report acquiring 
their most recent supply of pain relievers from a friend or relative, and among them, over 
three quarters report that their friend or relative had acquired the pain relievers from a doctor 
[2], [5].
Considerable research has been conducted on the public health problems surrounding 
nonmedical use of pharmaceutical opioids. Large scale primary data collection methods, 
such as the NSDUH, the National Poison Data System (NPDS), and the Drug Abuse 
Warning Network (DAWN) have enabled a large number of analyses on the prevalence [6], 
[7], characteristics [8], [9], and adverse outcomes [10], [11] associated with nonmedical 
opioid use. Smaller, independent studies have measured prevalence among a number of 
prominent subpopulations, such as physicians [12], anesthesiologists [13], and student 
pharmacists [14], and have been instrumental in identifying additional factors that are 
relevant to this public health problem. These factors include polydrug use [15], mental 
health problems [16], social support [17], and routes of diversion [18].
Because of the large number of data sources available for studying nonmedical opioid use 
and the wide range of relevant factors, systematic organization of data sources is needed to 
facilitate ongoing research, analysis, and evaluation of this public health problem. Initial 
efforts organize data sources according to topic [19] and geographical scale [20], however a 
systematic approach has not yet been employed in the search and categorization of existing 
data sources. This work provides a systematic approach to the collection and categorization 
of data sources along a set of prominent topics in the field, providing a guide for researchers, 
policy-makers, and others who seek data on various aspects of the nonmedical use of 
pharmaceutical opioids in the United States.
Schmidt et al. Page 2
Rev Health Care. 
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Methods
This work was conducted to advance a larger research project which uses System Dynamics 
modeling to investigate the nonmedical use of pharmaceutical opioids in the United States. 
System Dynamics is a computer simulation methodology that describes a system in terms of 
stocks and flows which are governed by differential equations [21], [22]. This methodology 
is capable of incorporating a large range of available data into a systems-level model that 
represents the global dynamics of the system of interest [23].
Keyword Searches
To provide empirical support for the specification of a System Dynamics model, data 
sources were systematically sought out for their relevance to the diversion, nonmedical use, 
and adverse outcomes associated with pharmaceutical opioids in the United States. This 
investigation began with a list of keywords which were identified from the project's 
previously established collection of electronic resources, including journal articles, 
government documents, and reports regarding the public health problem of nonmedical 
opioid use. The list was compiled by scanning through documents for words listed in a 
“keywords” field, and was then simplified by omitting keywords of non-opioid drugs and 
substances, specific drug formulation names (e.g., Fentanyl, OxyContin), words pertaining 
specifically to medical treatment, and other words that were not directly related to the 
phenomena of interest (e.g., screening instrument, prevention, mental health, triplicates). 
The final list of keywords was grouped into diversion, nonmedical use, and adverse outcome 
categories, and used in three PubMed searches for peer-reviewed academic articles 
published between January 1, 1995, and May 1, 2012. The specific searches, submitted to 
PubMed® in May of 2012, are included in Table 1.
Source Filtration
Literature searches conducted in PubMed® returned a large number of hits regarding 
diversion (1,506), nonmedical use (15,512), and adverse outcomes (4,508). These studies 
were filtered by a team of three graduate students with the following search criteria: All 
journal articles were required to be peer reviewed, to be available in the English language, to 
contain quantitative data on human subjects, to have a minimum sample size of 30 
participants, and to have direct relevance to the US population. Studies on medical treatment 
with pharmaceutical opioids were excluded, including treatment for opioid or opiate 
dependence. Articles which analyzed secondary data were also excluded, but the primary 
data sources used were noted for inclusion in the categorization process described below.
A filtered collection of 92 articles meeting the search criteria were evaluated qualitatively by 
two graduate students, who independently created lists of the most prominent topics. The 
two lists were compared, and differences between them were resolved through discussion, 
resulting in a final list of 20 topics. These topics were grouped for their relevance to 
diversion, nonmedical use, and adverse outcomes, as they appear in Tables 2 through 4. At a 
later time point, two design features were identified as salient, as several articles reported 
analyses of longitudinal and/or geographic trends. These attributes are included in the 
Appendix.
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Categorization
A list of sources was created, including the 92 filtered articles and 42 additional primary 
sources that had been noted during the filtration process. Each source was categorized by the 
geographical scale at which it was collected, and for its relevance to any of the 20 topics and 
2 design attributes. Closer examination of articles during this phase resulted in several more 
instances of exclusion, for reasons of confounding (e.g., opioids with heroin; nonmedical 
with medical use), absence of original data (e.g., review articles, secondary analyses), or 
research on excluded topics (e.g., search algorithms for post-marketing surveillance, 
healthcare costs among nonmedical users). Several primary sources were also excluded 
during the categorization phase, for reasons of duplication (e.g., Veterans Affairs and 
Veterans Health Administration), and measurement of excluded topics (e.g., adverse events, 
which imply medical use). This resulted in a final list of 35 original research articles as well 
as 22 primary data sources, categorized in Tables 2 through 4, and the Appendix. For 
primary data sources (i.e., those not specific to any journal article), additional references 
were sought to establish whether they satisfied each scale, topic, and attribute in the tables.
Results
The following sections describe the data sources that were found to be relevant to various 
aspects of diversion, nonmedical use, and the adverse outcomes associated with 
pharmaceutical opioids, as shown in Tables 2 through 4. Data sources' capacity for 
geographical and longitudinal trend analysis will not be discussed in detail, but results are 
available in the Appendix. In all tables, row headings indicate prominent topics, while 
column headings indicate the highest scale at which the data source is relevant. Sources are 
arranged by bullets within a table cell to differentiate large scale primary sources from 
independent studies. Bullets containing the name of a primary source are followed by 
informational resources and example analyses. Bullets without a source name contain the 
independent studies that have been conducted for a given topic and scale level. Sources that 
can be accessed publicly are indicated with bold type font, and sources that do not strictly 
limit responses to pharmaceutical opioids, but imply them (e.g., listing “pain killers,” “pain 
relievers,” or “narcotics other than heroin”) are indicated with an asterisk. Key highlights 
among the predominant data sources for nonmedical use, diversion, and adverse outcomes 
are provided in the sections below.
Nonmedical Use Table
Table 2 categorizes data sources by central topics in the prevalence, frequency, and 
characteristics of those who use pharmaceutical opioids nonmedically in the United States. 
Because of the illegal nature of nonmedical opioid use, its prevalence is measured most 
often through self-report surveys, especially among non-patient populations [24], [25], [26], 
[27], [28], [29], [30], [31]. Among patient populations, prevalence of nonmedical use is 
measured with either survey [16], [24], [32] or toxicology methods, such as urine screening 
[24], [33], [34]. In addition to prevalence, some surveys ask about the frequency of 
nonmedical use during a recent period of time [26], [35], [36], [37], [38], [39], [40], or about 
the age of initiation [5], [41], [42] or duration [43] of nonmedical use. Other studies measure 
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prevalence among more specific populations, such as parturients [44], club goers [36], 
student pharmacists [14], healthcare workers [12], [13], and probationers [17].
A great amount of attention is paid to determining the characteristics of nonmedical opioid 
users [8], [45], [46]. Not surprisingly, a large number of data sources capture demographic 
information, which allows nonmedical use of pharmaceutical opioids to be studied in terms 
of age, gender, and racial/ethnic differences. Additional characteristics include income [42], 
[47], employment status [27], [28], [42], [47], [48], housing status [42], [48], educational 
performance [46] and attainment [16], physical health [16], [30], [31], [47], mental health 
[16], [17], [30], [31], [32], [34], [46], and legal or behavioral problems [34], [42], [47]. 
Social characteristics include marital status [16], [27], [28], [49], family structure [27], [28], 
[49], social support [17], urbanicity [50] and community size [9], as well as college-level 
characteristics [51]. Several studies have also measured motivations for nonmedical use, 
such as pain relief, experimentation, or “getting high” [9], [14], [24], [37], [38], [52], as well 
as attitudes about the perceived risk of using pharmaceutical opioids nonmedically [9]. Two 
additional topics of importance include common routes of administration [9], [13], [37], 
[38], [48], [53], [54], [55], [56], [57] and polydrug use behaviors [5], [13], [15], [29], [35], 
[38], [42], [43], [58], [59] which make the potential harm of nonmedical use especially high 
[43].
Diversion Table
Table 3 provides categorization of sources based on their relevance to the diversion of 
pharmaceutical opioids. Diversion is defined as the transfer of pharmaceutical opioids from 
their lawful purpose to illicit use [60]. The manufacturing and delivery of pharmaceutical 
opioids to retail locations is monitored by the Drug Enforcement Agency (DEA) through the 
Automation of Reports and Consolidated Orders System (ARCOS) [61]. Various routes of 
diversion can disrupt the supply chain of pharmaceutical opioids between their production 
and lawful distribution to patients. Large scale thefts are recorded by the DEA [62], [63] and 
diversion by healthcare workers is captured in police records [64], through the RADARS® 
key informant network [65], and in independent studies [18], [66].
Other routes of diversion can be measured through self-reports of individuals who have 
acquired pharmaceutical opioids through illicit means. Monitoring the Future [39], [67] the 
National Survey of Drug Use and Health (NSDUH) [68], [69], [70], the National Addictions 
Vigilance Intervention and Prevention Program (NAVIPPRO) [57], and the Delaware 
School Survey [30], [31] all ask respondents questions regarding the source of nonmedically 
used pharmaceutical opioids. Diversion can also be measured indirectly by asking 
respondents whether they believe pharmaceutical opioids could be easily acquired for 
nonmedical use [9], [30], [31], and through post-marketing surveillance techniques such as 
monitoring online forums [71] and measuring the prevalence of accidental poisonings [5], 
[10], [72], [73], [74] and substance abuse treatment [43], [57], [75].
Adverse Outcomes Table
Table 4 categorizes data on a variety of adverse outcomes associated with pharmaceutical 
opioids. Topics included in this table are not meant to imply causal relationships, but 
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indicate a variety of negative outcomes that have been found to be associated with 
nonmedical opioid use, such as fatal and nonfatal opioid poisonings, substance use 
disorders, addiction relapse, violence and suicide. A common measurement for many of 
these adverse outcomes is the International Classification of Diseases (ICD-10) [76], which 
contains medical codes for opioid dependence, opioid abuse, and unintentional poisonings 
due to methadone, heroin, or “other opioids.” These codes are the basis for much of the data 
collected through hospital medical records [77], [78], [79], insurance claims [79], and death 
certificates which indicate instances where unintentional opioid poisoning was recorded as 
the primary cause of death [80], [81]. Data regarding emergency department visits for 
nonfatal opioid poisonings can be accessed through the Drug Abuse Warning Network 
(DAWN) [82], and data regarding fatal opioid poisonings are available through the CDC's 
National Vital Statistics System (NVSS) [83].
Other common measurements of adverse outcomes include those gathered by poison call 
centers, treatment centers, and surveys. The National Poison Data System (NPDS) [84] is a 
prominent national data source for nonfatal opioid poisonings, collecting data from 57 
poison call centers throughout the United States. Information regarding the prevalence of 
opioid use disorders [43], [57], [85] as well as addiction relapse [12], [57] are captured by 
substance abuse treatment centers, such as those monitored by the National Addictions 
Vigilance Intervention and Prevention Program (NAVIPPRO®) [86]. Several questions on 
the NSDUH can also be used to determine whether participants have opioid dependence 
[40], [47], [68], and independent studies have used surveys to measure outcomes such as 
dependence and withdrawal symptoms [26], [30], [35], [38], and witnessing or experiencing 
an overdose [17].
Discussion
The categorization of data sources in Tables 2 through 4 can serve as a guide for those who 
seek data sources regarding the diversion, nonmedical use, and adverse outcomes associated 
with pharmaceutical opioids in the United States. Global trends in data source coverage are 
illustrated as a bi-partite network in Figure 1. Topics from Tables 2 through 4 are listed on 
the left, and primary data sources are listed on the right. Connections indicate coverage of 
topics by data sources, illustrating (1) variety among sources in the number of topics they 
cover, as well as (2) variety among topics in the number of sources that cover them. The 
topical coverage of each source is shown by the number of connections that stem from it. 
Large scale sources such as NAVIPPRO, RADARS, MTF, and DAWN collect data that is 
relevant for many topics within the pharmaceutical opioid public health problem. Other 
sources in this review, such as the National Inpatient Survey (NIS), Automation of Reports 
and Consolidated Orders System (ARCOS), the American College of Medical Toxicology 
(ACMT), and Veterans Affairs (VA) Medical records, are relevant to only one topic.
In a similar manner, the source coverage of each topic is shown by the number of 
connections that lead to it. Some topics are covered by more data sources than others. More 
than half of the primary sources contain data regarding individual characteristics of those 
exhibiting behaviors of nonmedical use of pharmaceutical opioids. Many sources also cover 
prevalence, opioid use disorders, illicit sources, social characteristics, and routes of 
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administration. By contrast, addiction relapse, domestic impact, and transaction tracking 
were each covered by only one primary data source. The scarcity of sources covering some 
topical areas may be due to sufficiency of a single source, such as the Drug Enforcement 
Agency's ARCOS tracking system, or mortality data from National Vital Statistics System 
(NVSS). However, scarcity of sources covering other topical areas may indicate a need for 
additional data collection, such as addiction relapse or polydrug use, both of which have 
been found to be pertinent to this public health problem [12], [15].
Limitations
Much effort was made to conduct an exhaustive search for data sources and a 
comprehensive examination of their relevance to prominent topics in the field. However, the 
current work is subject to several limitations. First, the original list of keywords stemmed 
from an existing library that was not created for the purpose of this project. Second, 
although PubMed® is updated daily and has been identified as an optimal tool for electronic 
searches [87], this search engine focuses primarily on medicine and biomedical sciences, 
and may have excluded some relevant sources. Data sources may also have been 
inadvertently excluded if their direct relevance to nonmedical opioid use was not discussed 
in peer-reviewed academic literature. Third, the identification of prominent topics was 
conducted subjectively by members of a larger research project which uses System 
Dynamics to investigate the nonmedical use of pharmaceutical opioids in the United States. 
Filtration and categorization of sources may also have been subject to human error.
Additional limitations to this work stem from its boundaries of inclusion. A specific focus 
on nonmedical use of pharmaceutical opioids led to the exclusion of data sources regarding 
medical use of pharmaceutical opioids for pain treatment as well as for treatment of 
individuals exhibiting opioid or opiate abuse. These boundaries made the project much more 
feasible, but preclude its usefulness for these related topics. Searches in PubMed were also 
limited to the time period between January 1995 and April 2012.
Conclusions
This work offers a systematic categorization of data sources pertaining to the nonmedical 
use of pharmaceutical opioids in the United States. Data sources are categorized according 
to their relevance to a number of prominent topics in the areas of diversion, nonmedical use, 
and adverse outcomes associated with pharmaceutical opioids. Sources are also organized 
according to their capacity for geographical and longitudinal trend analysis. This 
categorization, provided in Tables 2 through 4, and the Appendix, can be used as a guide for 
researchers, policy makers, and others who seek data regarding various aspects of this public 
health problem. In addition, these tables show the distribution of data coverage across 
topics, indicating which topics are covered by more and fewer sources. This work serves to 
increase awareness of data sources that exist, suggests topics that may require additional 
data collection, and is hoped to facilitate ongoing research, analysis, and evaluation of this 
public health problem.
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Appendix
Appendix
Categorization of Data sources by ideographical and Longitudinal Design Attributes
TOPICS: Data 
Sources By 
Geographical And 
Longitudinal 
Design Attributes
SCALE†
National State Multi-center Single-Center
Geographical 
Trends in Opioid 
Abuse
□ ARCOS [62] □ CDAS*[95], [30], 
[31]
□ Insurance Claims 
Data [117]
□ [96]
□ DAWN [82], [6]
□ MIT* [9]
□ NAVIPPRO [86], [57], 
[90]
□ NIS [110], [78]
□ NPDS [10], [84], [111], 
[115]
□ NSDUH* [116]
□ NVSS [83], [97]
□ ThDS [98], [99]
□ VA Medical Records 
[112]
Longitudinal‡ 
Trends in Opioid 
Abuse
□ ARCOS [62] □ CDAS* [95], [30], 
[31]
□ Insurance Claims 
[79], [119]
□ Medical Examiners 
[80]
□ [12]
□ RADARS® [120] □ [121]
□ DAWN [82], [6], [89] □ [13]
□ MIT* [9]
□ NAVIPPRO [86][57]
□ NESARC [91], [92]
□ NIS [110] [78]
□ NLAES [92]
□ NSDUH* [94] [3]
□ NVSS [83], [118]
□ TEDS [98] [99]
□ VA Medical Records 
[112]
□ [51]
Bold type font indicates a data source that is publicly available.
Acronyms Used: ARCOS (Automation of Reports and Consolidated Order System), CD AS (Center for Drug and Alcohol 
Studies), DAWN (Drug Abuse Warning Network), MIT (Monitoring the Future), NAVIPPRO (National Addictions 
Vigilance Intervention and Prevention Program), NESARC (National Epidemiologic Survey on Alcohol and Related 
Conditions), NIS (Nationwide Inpatient Sample), NLAES (National Longitudinal Alcohol Epidemiology Survey), NPDS 
(National Poison Data System), NSDUH (National Survey on Drug Use and Health), NVSS (National Vital Statistics 
System), RADARS® (Researched Abuse, Diversion and Addiction-Related Surveillance), TEDS (Treatment Episode Data 
Set), VA (Veterans Affairs)
*Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,” “pain 
medicine,” “pain relievers,” or “narcotics other than heroin”
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†Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more 
detailed information at smaller scales than are listed here.
‡
Longitudinal data sources include cohort or panel studies as well as `repeated cross sectional' studies.
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The Review in Brief
Clinical Question
This work offers a systematic categorization of data sources regarding the diversion, 
nonmedical use, and adverse outcomes associated with pharmaceutical opioids in the 
United States.
Type of Review
Systematic
Search of the Literature
Searches were conducted using PubMed®, with three sets of keywords:
1. Opioid/Opioids, Misuse/Noncompliance/Non-Compliance/Diversion
2. Opioid/Opioids, Deaths/Drug-Related Harm/Fatal Outcome/Mortality/
Overdose/Poisoning
3. Opioid/Opioids, Abuse/Aberrant Drug-Related Behaviors/Addiction/Abuse 
Liability/Problem Drug Use/Substance Use Disorders/ Substance-Related 
Disorders/Substance Related Disorders/ Nonmedical Use/Non-Medical Use/ 
Non-Medical Use
All sources were categorized according to their relevance to each of 20 topics and 2 
design features.
Conclusions
Tables cataloging data sources can be used to identify data relevant to specific topics in 
diversion, nonmedical use, and adverse outcomes, and for their capacity for geographical 
and longitudinal trend analysis. Global trends in coverage suggest that some topics have 
been measured plentifully, while others only minimally. The importance of some topics 
may warrant further data collection, including nonmedical use frequency, addiction 
relapse, polydrug use, availability of pharmaceutical opioids for nonmedical use, 
domestic impact, and transaction tracking.
Limitations
Searches were conducted solely in PubMed®, and were restricted to peer-reviewed 
academic journals. Keywords were identified through an existing collection of resources 
from a separate research project which uses computer simulation to investigate the public 
health problem of nonmedical opioid use. Identification of prominent topics was 
conducted subjectively by members of this simulation research project. Filtration and 
categorization of sources may also have been subject to human error.
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Figure 1. 
Bi-Partite Network depicting Connections between Large Scale Sources and Topics
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Table 1
Opioid Searches Submitted to PubMed® in May 2012
Opioid Searches
(1) (Opioid OR Opioids) AND (Misuse OR Noncompliance OR “Non-compliance” OR Diversion) AND (“1995/01/01”[Date - Publication] : 
“2012/05/01”[Date - Publication])
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